Five-year follow-up of a cohort of profoundly immunosuppressed patients discontinuing therapy for cytomegalovirus retinitis

AIDS. 2004 Feb 20;18(3):567-9. doi: 10.1097/00002030-200402200-00027.

Abstract

Potent antiretroviral therapy stimulates robust and durable immune reconstitution among profoundly immunosuppressed patients that is clinically important. Fifteen patients with cytomegalovirus retinitis (CMVR) were followed after discontinuing anti-cytomegalovirus therapy. No patients had progression or relapse for a median of 51 months. Survival from the diagnosis of CMVR was universal for up to 95 months, with an observation period averaging more than 6 years. The CD4 cell count continued to rise through the fourth year of follow-up.

MeSH terms

  • AIDS-Related Opportunistic Infections / drug therapy
  • AIDS-Related Opportunistic Infections / immunology*
  • Antiretroviral Therapy, Highly Active
  • CD4 Lymphocyte Count
  • Cytomegalovirus Retinitis / drug therapy
  • Cytomegalovirus Retinitis / immunology*
  • Follow-Up Studies
  • Humans
  • Immune Tolerance